Compounded vs. FDA-Approved Hormones: The Conversation That Should Happen at Every Consult

Walk into one menopause clinic and you’ll be told compounded “bioidentical” hormones are gentler, safer, and more natural than anything the FDA has approved. Walk into another and you’ll be told compounded hormones are unregulated, unproven, and a marketing trick. Both versions can’t be true.

Here is what the major medical societies actually say, what the law actually allows, and how a careful clinic thinks about choosing between a compounded prescription and an FDA-approved one. This is the conversation that should happen at every BHRT consult — and often doesn’t.

A compounded medication is one a licensed pharmacist mixes for an individual patient, usually for a dose, formulation, or combination not commercially available. Compounding is older than the modern pharmaceutical industry, and it is legal — federally regulated under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, with quality standards set primarily by United States Pharmacopeia chapters 795 and 797.

Compounded is not a synonym for bioidentical. “Bioidentical” describes a molecule’s chemical structure: estradiol, estrone, estriol, progesterone, and testosterone are all bioidentical to the hormones your body makes. The FDA has approved bioidentical estradiol patches, gels, sprays, vaginal rings, and oral micronized progesterone for decades. When a clinic says “we prescribe bioidentical hormones,” that may or may not mean the prescription is compounded — and most patients don’t hear it spelled out.

Three authoritative bodies have published clear positions on compounded bioidentical hormone therapy in the last six years. They don’t say compounded hormones are dangerous. They say something more specific.

The 2020 National Academies of Sciences, Engineering, and Medicine (NASEM) report, commissioned by the FDA, concluded there was a lack of high-quality evidence supporting routine clinical use of compounded bioidentical hormone therapy. The committee recommended prescribing be restricted to two situations: documented allergy to an ingredient in an FDA-approved product, and clinical need for a dose or formulation not commercially available. Patient preference alone, the report said, should not drive the decision.

The Menopause Society’s 2022 Hormone Therapy Position Statement echoed that framing. It identified safety concerns with compounded products — minimal government oversight, risk of overdosing or underdosing, impurities, lack of efficacy data, no risk label — and said compounded options could be considered in the same two narrow situations.

ACOG’s November 2023 Clinical Consensus No. 6 is the most recent and the most pointed. It states that compounded bioidentical menopausal hormone therapy “should not be prescribed routinely when FDA-approved formulations exist,” and that clinicians should counsel patients that FDA-approved products are recommended over compounded ones. If a patient still requests compounded after that counseling, ACOG says, informed consent should cover the specific risks of compounding.

Three independent groups, reviewing the same evidence, landed in the same place: skeptical of routine use, open to specific exceptions.

Compounding is legal. It has its own federal regulatory framework. Compounded preparations are not unregulated; they are regulated differently than mass-manufactured drugs.

The 2013 Drug Quality and Security Act formalized two compounding tiers:

• 503A pharmacies prepare patient-specific prescriptions. They are licensed and overseen primarily by state boards of pharmacy and are expected to follow USP 795 (non-sterile) and USP 797 (sterile) standards. Oversight varies by state, and the FDA does not routinely inspect 503A pharmacies the way it inspects drug manufacturers.
• 503B outsourcing facilities can compound in larger batches without a patient-specific prescription, are registered directly with the FDA, are inspected by the FDA on a risk-based schedule, and must follow current Good Manufacturing Practice (cGMP) standards — essentially the same quality regime as commercial pharmaceutical manufacturers.

The practical implication: not all compounding pharmacies are equivalent. A 503B outsourcing facility operating under cGMP is held to a more demanding quality standard than a typical 503A community pharmacy. When a clinic prescribes a compounded hormone, which pharmacy is filling it is a real variable, and one most patients have never been asked about.

What compounding still doesn’t have — at either tier — is the randomized clinical trial data that supports FDA approval. A compounded estradiol cream may contain the same molecule as an FDA-approved estradiol gel, but it has not been studied as a finished product for absorption or long-term outcomes. Recent comparisons of compounded transdermal estradiol creams against FDA-approved gels and patches have found meaningful variability in serum estradiol exposure — the kind of variability that’s hard to monitor without serial labs.

Reading the NASEM, NAMS, and ACOG positions back-to-back, the legitimate use cases are narrow but real:

Documented allergy to an excipient. Some FDA-approved hormone products contain peanut oil, sesame oil, alcohol, or specific dyes and preservatives. A patient who reacts to a vehicle ingredient — not the hormone itself — may genuinely need a compounded version made with a different base.

A dose or formulation not commercially available. The FDA-approved estradiol patch comes in fixed doses (0.025, 0.0375, 0.05, 0.075, 0.1 mg/day). Most patients fit fine inside that ladder. A few don’t. Testosterone for women is the clearest example: there is no FDA-approved testosterone product for women in the US, so prescribing for postmenopausal hypoactive sexual desire disorder happens either by using a small fraction of a male product or by compounding a low-dose female preparation. The Menopause Society and the 2019 Global Consensus Statement both acknowledge this is one of the situations where compounding is reasonable, because the alternative is not “use an approved product instead” — there is no approved product to use.

Specific clinical circumstances like a sensitivity to commercial micronized progesterone in peanut oil (Prometrium), an inability to tolerate transdermal adhesives, or a documented need for a combination not sold as a single product.

Outside those situations, the published evidence does not support choosing a compounded preparation over an FDA-approved one as a default.

A few things should raise a careful eyebrow:

Compounded estrogen pellets. Subcutaneous estrogen and testosterone pellets are heavily marketed in the wellness space, and the major societies are explicit about them. ACOG advises against routine use. The Menopause Society identifies supraphysiologic blood levels, mood changes, hair changes, and unscheduled bleeding as documented risks. The 2019 Global Consensus Statement on testosterone in women specifically recommends against pellets because they tend to push hormone levels above the normal female range. None of this means a pellet is dangerous in every instance — but it does mean the data do not support pellets as a first-line approach for most patients.

“Custom saliva or hair test-driven” compounding. When a clinic uses non-validated tests to justify a custom-mixed cocktail that no FDA-approved product would deliver, the layered claim — that an individual’s hormones need a unique formulation only this pharmacy can produce — is doing more marketing than medicine. The 2020 NASEM report flagged this pattern specifically.

Compounding because it’s marketed as “natural” or “safer.” Estradiol is estradiol whether it was made by a 503B facility under cGMP or compounded by a 503A pharmacy. The molecule doesn’t know its origin. The marketing language around “natural” and “plant-derived” applies equally to most FDA-approved bioidentical products. Choosing compounded over approved for the marketing reason alone is not supported by any of the three society positions.

For the great majority of patients, an FDA-approved bioidentical product is the default at Naya — transdermal estradiol patches, gels, or sprays for systemic estrogen; oral micronized progesterone for women with a uterus; vaginal estradiol for localized symptoms; FDA-approved testosterone products dosed carefully for men. These options have decades of trial data behind them, predictable absorption, FDA-mandated adverse event reporting, and the labeling clarity that the February 2026 label change refined.

Compounded prescriptions have a place in the practice, and it is the place the societies describe. A documented allergy to a vehicle ingredient. A dose that the commercial ladder doesn’t reach. Testosterone therapy for women, where no approved female product yet exists in the US. In those situations, the prescription goes to a vetted compounding pharmacy that meets — or exceeds — USP 795/797 standards, the formulation is chosen deliberately, and follow-up labs verify the patient is actually landing in the physiologic range the protocol intends.

What doesn’t happen is a default to compounded products because they sound better in the marketing. Pellets are not part of the standard protocol for the reasons the major societies have laid out. And when a patient comes in asking specifically about a compounded option they’ve seen advertised elsewhere, the conversation is the one ACOG describes: an honest accounting of what’s known, what isn’t, and which approach the evidence actually supports for them.

If you’ve been told compounded hormones are uniquely safe — or uniquely dangerous — and want a straight answer, that’s exactly the kind of conversation we have at Naya Wellness. Carolyn Pampalone, MSN, FNP-BC, has spent nearly two decades in women’s health and hormone care and can help you sort out whether your situation calls for an FDA-approved product, a compounded one, or a different approach altogether. You can talk it through at our Chatsworth or Santa Barbara clinics, or by telehealth across California.

Two California locations and statewide telehealth — click a card to view details, or call to schedule a consult.